Mesenchymal stem cells: immune evasive, not immune privileged

Area of Science:

• Immunology
• Cell Therapy

Background:

• Mesenchymal stem/stromal cells (MSCs) possess immunomodulatory properties beneficial for treating inflammatory diseases.
• MSCs were traditionally considered immune privileged, facilitating allogeneic transplantation and off-the-shelf therapies.
• Recent findings indicate potential immune rejection of allogeneic MSCs, challenging the immune privilege concept.

Purpose of the Study:

• To investigate the immune privilege status of MSCs.
• To explore the impact of MSC immune rejection on allogeneic therapy efficacy.
• To determine if strategies enhancing MSC persistence improve clinical outcomes.

Main Methods:

• Review of recent studies on MSC immunogenicity and immune rejection.
• Analysis of clinical data regarding autologous versus allogeneic MSC therapy outcomes.
• Evaluation of the 'hit and run' mechanism versus prolonged MSC persistence.

Main Results:

• Evidence suggests MSCs may not be completely immune privileged, as antibodies and rejection of allogeneic MSCs have been observed.
• The influence of donor MSC rejection on therapeutic efficacy remains unclear.
• No definitive clinical advantage of autologous over allogeneic MSCs has been established.

Conclusions:

• The immune privilege of MSCs is questionable, necessitating further research into immune responses against allogeneic MSCs.
• Strategies to protect MSCs from immune detection and prolong their in vivo persistence may enhance therapeutic efficacy.
• Improving MSC persistence could prevent patient sensitization to donor antigens and optimize treatment outcomes.